Connect Biopharma is trading 7.1% down at $2.57, following a pullback after two consecutive strong sessions.
- The stock reached $2.76 on September 2.
- No new company-specific announcement explaining the September 3 decline was identified.
- Investors remain focused on topline results from the Phase 2 Seabreeze STAT asthma and COPD studies, which the company expects to report in September 2026; broader biotechnology sentiment is positive.